Discordant associations between slco1b1 521t→c and plasma levels of ritonavir-boosted protease inhibitors in aids clinical trials group study A5146

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 209-216

  Zhang, Xinyan ^a   Tierney, Camlin ^a   Albrecht, Mary ^b   Demeter, Lisa M ^c   Morse, Gene ^d   Difrancesco, Robin ^d   Dykes, Carrie ^c   Jiang, Hongyu ^e   Haas, David ^e,f  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f University of Nashville School of Medicine   (United States)

Author keywords

HIV therapy; pharmacogenomics; protease inhibitors

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; FOSAMPRENAVIR; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; RITONAVIR; SAQUINAVIR;

AGED; ARTICLE; CAUCASIAN; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; FEMALE; GENETIC ASSOCIATION STUDIES; HIV PROTEASE INHIBITORS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; RITONAVIR;

EID: 84875199086     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318280d0ad     Document Type: Article

References (49)

1. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998; 37: 3594-3601.
2. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998; 101: 289-294.
3. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010; 20: 112-120.
4. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002; 30: 795-804.
5. Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001; 29: 754-760.
6. Gupta A, Mugundu GM, Desai PB, et al. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008; 36: 1172-1180.
7. Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001; 276: 33309-33312.
8. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007; 8: 787-802.
9. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010; 20: 217-230.
10. Kohlrausch FB, de Cassia Estrela R, Barroso PF, et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010; 69: 95-98.
11. Rakhmanina NY, Neely MN, Van Schaik RH, et al. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011; 33: 417-424.
12. dbSNP-Short Genetic Variations. Available at: http://www.ncbi.nlm. nih.gov/projects/SNP/. Accessed January 5, 2013.
13. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002; 30: 883-891.
14. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27: 383-391.
15. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11: 773-779.
16. Anderson PL, Aquilante CL, Gardner EM, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009; 64: 1071-1079.
17. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIVinfected adults: a pilot study. J Acquir Immune Defic Syndr. 2006; 42: 441-449.
18. Solas C, Simon N, Drogoul MP, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol. 2007; 64: 353-362.
19. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A51 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005; 78: 605-618.
20. Birdwell KA, Grady B, Choi L, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics. 2012; 22: 32-42.
21. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97: 3473-3478.
22. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drugdrug interactions. J Clin Pharmacol. 1999; 39: 1203-1211.
23. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000; 38: 69-74.
24. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002; 53: 526-534.
25. Zhu D, Taguchi-Nakamura H, Goto M, et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther. 2004; 9: 929-935.
26. Rodriguez NS, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-.T polymorphism at the multidrug resistance gene Clin Infect Dis. 2006; 42: 291-295.
27. Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol. 2002; 54: 610-616.
28. Pauli-Magnus C, Feiner J, Brett C, et al. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther. 2003; 74: 487-498.
29. Mai I, Perloff ES, Bauer S, et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2004; 58: 548-553.
30. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of longterm responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J Infect Dis. 2005; 192: 1931-1942.
31. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001; 7: 584-590.
32. Meyer zu Schwabedissen HE, Kim RB. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharmacol. 2009; 6: 1644-1661.
33. Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004; 279: 38379-38385.
34. Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008; 36: 169-181.
35. Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral- experienced, HIV-1-infected patients. AIDS. 2009; 23: 357-368.
36. Haas DW, Wilkinson GR, Kuritzkes DR, et al. A multi-investigator/ institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials. 2003; 4: 287-300.
37. SeattleSNPs. NHLBI Program for Genomic Applications. SeattleSNPs, Seattle, WA. Available at: pga.gs.washington.edu/
38. NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical Research. Available at: http://grants.nih.gov/grants/guide/notice-files/not-od- 01-053.html. Accessed January 6, 2013.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995; 57: 12.
40. Oshiro C, Mangravite L, Klein T, et al. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010; 20: 211-216.
41. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73: 554-565.
42. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005; 78: 342-350.
43. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16: 873-879.
44. Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82: 726-733.
45. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78: 330-341.
46. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77: 468-478.
47. Katz DA, Carr R, Grimm DR, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006; 79: 186-196.
48. Xiang X, Jada SR, Li HH, et al. Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics. 2006; 16: 683-691.
49. Oswald S, Scheuch E, Cascorbi I, et al. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B. 2006; 830: 143-150.